{
  "id": "602346eb1cb411341a000090",
  "type": "list",
  "question": "A combination of which two drugs was tested in the IMbrave150 trial?",
  "ideal_answer": "IMbrave150 trial tested a combination of atezolizumab and bevacizumab for advanced hepatocellular carcinoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33442538",
    "http://www.ncbi.nlm.nih.gov/pubmed/32349374",
    "http://www.ncbi.nlm.nih.gov/pubmed/34853653",
    "http://www.ncbi.nlm.nih.gov/pubmed/34798793",
    "http://www.ncbi.nlm.nih.gov/pubmed/33663220",
    "http://www.ncbi.nlm.nih.gov/pubmed/34522691",
    "http://www.ncbi.nlm.nih.gov/pubmed/33139264",
    "http://www.ncbi.nlm.nih.gov/pubmed/34051880",
    "http://www.ncbi.nlm.nih.gov/pubmed/33549983",
    "http://www.ncbi.nlm.nih.gov/pubmed/34771637",
    "http://www.ncbi.nlm.nih.gov/pubmed/32984090",
    "http://www.ncbi.nlm.nih.gov/pubmed/33213161",
    "http://www.ncbi.nlm.nih.gov/pubmed/34377156",
    "http://www.ncbi.nlm.nih.gov/pubmed/34167423",
    "http://www.ncbi.nlm.nih.gov/pubmed/34189869",
    "http://www.ncbi.nlm.nih.gov/pubmed/34245216"
  ],
  "snippets": [
    {
      "text": "A successful phase III trial for the combination of atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32349374",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ndeed, preliminary results from phase I studies of lenvatinib plus pembrolizumab and atezolizumab plus bevacizumab have proved favorable, prompting phase III investigations in the frontline setting, and for atezolizumab plus bevacizumab, these positive findings have been substantiated by recent reporting of phase III data from IMbrave150.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32984090",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The approval was based on data from Study IMbrave150, which randomly allocated (2:1) patients to receive either atezolizumab plus bevacizumab (atezolizumab-bevacizumab) or sorafenib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33139264",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In study IMbrave150, the combination of atezolizumab and bevacizumab was successfully used compared to sorafenib in the first-line treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33213161",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The IMbrave150 trial set atezolizumab-bevacizumab as a new standard-of-care first-line treatment for unresectable HCC patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34798793",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A recent phase III trial (IMbrave150) showed that combination immunotherapy with atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy, and worldwide approval is expected soon.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33442538",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, in 2020, the IMbrave150 trial demonstrated that combination therapy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) and bevacizumab (anti-vascular endothelial growth factor [VEGF]) is superior to sorafenib, a single anti-programmed death 1/PD-L1 antibody inhibitor used as an anti-cancer monotherapy for HCC treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34853653",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The results of a recent Phase III (IMbrave150) trial favor the combination of atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34522691",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nt Phase III (IMbrave150) trial favor the combination of atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34522691",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ation treatment with atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF) in the recent IMbrave150 study was shown to be effective with an acceptable safety profile in patients with unresectable HCC. Herein, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33663220",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In light of positive efficacy and safety findings from the IMbrave150 trial of atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34377156",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he IMbrave150 trial recently showed that, among patients with previously untreated unresectable HCC, treatment with atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib monotherapy. In addition, t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33549983",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab. The anal",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34771637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "I trial (IMbrave150) showed that combination immunotherapy with atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy, and worldwide approval is expected soon. This review descri",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33442538",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: IMbrave150 is a phase III trial that assessed atezolizumab\u00a0+\u00a0bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC) and demonstrated a significant improvement in clinic",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A successful phase III trial for the combination of atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32349374",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " important. We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial, which has already shown significant overall survival and progression-free survival benefits with this combination therapy.METHODS: We did an open-label, randomised, phase 3 trial in 111 hospitals and cancer centres across 17 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34051880",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIM: A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34245216",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The phase 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34771637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CC). In this study, we evaluated this therapeutic combination in a real-world setting, with a focus on patients who did not meet the IMbrave150 eligibility criteria.METHODS: In this multicenter study, patients with unresectable HCC treated with atezolizumab plus bevacizumab between October 2020 and May 2021 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34245216",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The efficacy of the combination was first assessed in the phase Ib GO30140 study, and the combination was then proven superior to the prior standard of care, sorafenib, in the phase III IMbrave150 trial.Areas covered: This article focuses on the mechanism of action of atezolizumab and bevacizumab, their synergistic action, and the two clinical trials leading to approval.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34167423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combination treatment with atezolizumab (targeting PD-L1) and bevacizumab (targeting VEGF) in the recent IMbrave150 study was shown to be effective with an acceptable safety profile in patients with unresectable HCC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33663220",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "atezolizumab, bevacizumab"
}